RTD Financial Advisors Inc. cut its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 57.7% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 6,732 shares of the biopharmaceutical company’s stock after selling 9,176 shares during the period. RTD Financial Advisors Inc.’s holdings in Bristol Myers Squibb were worth $420,000 as of its most recent SEC filing.
Other large investors also recently bought and sold shares of the company. Boltwood Capital Management raised its stake in shares of Bristol Myers Squibb by 2.5% during the 3rd quarter. Boltwood Capital Management now owns 7,107 shares of the biopharmaceutical company’s stock worth $443,000 after buying an additional 170 shares during the period. KCM Investment Advisors LLC increased its holdings in Bristol Myers Squibb by 0.8% in the 4th quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company’s stock worth $1,126,000 after acquiring an additional 174 shares in the last quarter. Sandy Cove Advisors LLC raised its position in Bristol Myers Squibb by 4.7% during the second quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company’s stock worth $227,000 after acquiring an additional 176 shares during the period. Investment Research Partners LLC raised its position in Bristol Myers Squibb by 1.4% during the fourth quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company’s stock worth $708,000 after acquiring an additional 179 shares during the period. Finally, Key Financial Inc lifted its holdings in Bristol Myers Squibb by 2.4% during the first quarter. Key Financial Inc now owns 7,939 shares of the biopharmaceutical company’s stock valued at $482,000 after purchasing an additional 183 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.
Trending Headlines about Bristol Myers Squibb
Here are the key news stories impacting Bristol Myers Squibb this week:
- Positive Sentiment: Bristol Myers reported that its ZENBEXUS (iberdomide) combination achieved superior progression-free survival versus standard of care in the Phase 3 EXCALIBER-RRMM trial for relapsed or refractory multiple myeloma. The results also showed high minimal residual disease-negative complete response rates and could support an application for accelerated FDA approval, strengthening BMY’s oncology pipeline. Bristol Myers Squibb Announces ZENBEXUS Phase 3 Results
- Positive Sentiment: J.P. Morgan reportedly assigned BMY a Buy rating, while recent commentary highlights the company’s oncology and hematology portfolio and its history of earnings surprises. These factors may support investor confidence in future growth and earnings. Bristol Myers Squibb Receives a Buy from J.P. Morgan
Bristol Myers Squibb Stock Performance
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The firm had revenue of $12.97 billion for the quarter, compared to analysts’ expectations of $11.74 billion. During the same period in the prior year, the firm posted $1.46 earnings per share. The firm’s quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Analysts forecast that Bristol Myers Squibb Company will post 6.91 EPS for the current year.
Bristol Myers Squibb Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be given a dividend of $0.63 per share. The ex-dividend date is Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.
Insider Activity at Bristol Myers Squibb
In related news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.05% of the company’s stock.
Wall Street Analyst Weigh In
A number of analysts have recently commented on the stock. Truist Financial reissued a “buy” rating and set a $70.00 target price (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Royal Bank Of Canada lifted their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “sector perform” rating in a report on Friday, July 31st. Cantor Fitzgerald cut their price objective on Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating for the company in a research note on Thursday. Morgan Stanley restated an “underweight” rating and issued a $41.00 target price (up from $40.00) on shares of Bristol Myers Squibb in a research report on Wednesday. Finally, Jefferies Financial Group lowered Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $64.96.
Check Out Our Latest Report on Bristol Myers Squibb
About Bristol Myers Squibb
Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.
Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.
Read More
- Five stocks we like better than Bristol Myers Squibb
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
